Nordic Biotech raises Second Biotech Venture Fund

Nordic Biotech Advisors ApS has announced the first closing of their second biotech fund - Nordic Biotech Venture Fund II K/S, NB II - with a committed capital of EUR 41,5 mill. A second closing is foreseen to take place within 12 months, and is expected to increase the fund size to EUR 75-90 mill. NB II will primarily invest in European biotech companies with a focus on drug development.

The investors in NB II include the European Investment Fund, the Danish Investment Fund, LD Pensions, W Capital Management AB and H. Lundbeck A/S, as well as the partners.

The first fund, Nordic Biotech K/S-, NB I, has invested in a number of rapidly developing biotech companies with compounds in early, mid and late stage clinical development, and retains significant ownership stakes in most of them. A number of the companies are currently positioned for major public and private offerings, M&A transactions as well as corporate partnerships.

For further information please contact:

Dr. Christian Hansen,

Partner

Tel: +45 70 20 12 63

Email: ch@nordicbiotech.com

Or visit: www.nordicbiotech.com